CWI1-2 drochloride is an IGF2BP2 inhibitor that binds IGF2BP2 and inhibits its interaction with m6A-modified target transcripts, induces apoptosis and differentiation, and shows promising anti-leukemic effects.
CWI1-2 (0-1 μM, 24 h) drochloride has good anti-leukemic efficacy[1].
CWI1-2 (5 mg/kg, i.v., once daily, 7-10 days) drochloride can significantly delay the onset of leukemia and prolong the survival time of BMT recipient B6.SJL (CD45.1) mice without any loss in body weight[1].
References:
[1]. Hengyou Weng, et al. The m6A reader IGF2BP2 regulates glutamine metabolism and represents a therapeutic target in acute myeloid leukemia. Cancer Cell. 2022 Dec 12;40(12):1566-1582.e10.